Accumulation of 5-phosphoribosyl-1-pyrophosphate in human CCRF-CEM leukaemia cells treated with antifolates
-
Add time:09/07/2019 Source:sciencedirect.com
Amido phosphoribosyltransferase (APRT) catalyzes the first step of the de novo biosynthesis of purine nucleotides, the conversion of 5-phosphoribosyl-1-pyrophosphate (PRPP) into 5-phosphoribosylamine (PRA). APRT is a valid target for development of inhibitors as anticancer drugs. We have developed a thin layer chromatographic assay for PRPP extracted from cells. Using coupling enzymes, PRPP with excess [2-14C]orotate (OA) is quantitatively converted to [2-14C]OMP and then [2-14C]UMP with hydrolysis of the PPi. The reaction products are isolated on poly(ethyleneimine)-cellulose (PEI-C) chromatograms. Human CCRF-CEM leukaemia cells growing in culture have been exposed to a number of antifolates and their effects upon cellular levels of PRPP determined. The steady-state level of PRPP measured in CCRF-CEM cells was 102±11 μM. Following addition of an antifolate to a culture, accumulation of PRPP in cells indicates the degree of inhibition of APRT. In human CCRF-CEM leukaemia cells, lometrexol (LTX), 2,4-diamino-6-(3,4,5-trimethoxybenzyl)-5,6,7,8-tetrahydro-quinazoline (PY899), methotrexate (MTX), Nα(4-amino-4-deoxypteroyl)-Nδ-hemiphthaloyl-l-ornithine (PT523), piritrexim (PTX), metoprine, 2,4-diamino-6-(3,4,5-trimethoxyanilino)-methylpyrido[3,2-d]pyrimidine (PY873) and multitargeted antifolate, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid (MTA) directly or indirectly induce inhibition of APRT indicated by time-courses for accumulation of PRPP to maximum values of 3–12-fold. These data indicate that LTX induces the most potent inhibition of APRT.
We also recommend Trading Suppliers and Manufacturers of 2'-(5''-phosphoribosyl)-5'-adenosine monophosphate (cas 15720-01-1). Pls Click Website Link as below: cas 15720-01-1 suppliers
Prev:BiomarkersInosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients
Next:The formation of a 1–5 phosphodiester linkage in the spontaneous breakdown of 5-phosphoribosyl-α-1-pyrophosphate) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Myricetin is a novel inhibitor of human inosine 5′-monophosphate dehydrogenase with anti-leukemia activity09/25/2019
- Hydrophilic-interaction liquid chromatography–tandem mass spectrometric determination of erythrocyte 5-phosphoribosyl 1-pyrophosphate in patients with hypoxanthine–guanine phosphoribosyltransferase deficiency09/24/2019
- Orotate phosphoribosyl transferase mRNA expression in oral squamous cell carcinoma and its relationship with the dihydropyrimidine dehydrogenase expression and the clinical effect of 5-fluorouracil09/10/2019
- ReviewOrotidine Monophosphate Decarboxylase – A Fascinating Workhorse Enzyme with Therapeutic Potential09/09/2019
- The formation of a 1–5 phosphodiester linkage in the spontaneous breakdown of 5-phosphoribosyl-α-1-pyrophosphate09/08/2019
- BiomarkersInosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients09/06/2019
- The catalytic effect of Mg2+ and imidazole on the decomposition of 5-phosphoribosyl-α-1-pyrophosphate in aqueous solution09/05/2019
- Sustainable synthesis of uridine-5′-monophosphate analogues by immobilized uracil phosphoribosyltransferase from Thermus thermophilus09/04/2019
- Carbocyclic phosphonate analogs of 2′,3′-dideoxyadenosine-5′-monophosphate as substrates of 5-phosphoribosyl-1-pyrophosphate (PRPP) synthetate09/03/2019


